Endogenous interleukin 6 can function as an in vivo growth-stimulatory factor for advanced-stage human melanoma cells

Clinical Cancer Research

Volumn 2, Issue 8, 1996, Pages 1417-1425

  Lu, Chao ^a,d   Sheehan, Capucine ^a   Rak, Janusz W ^a   Chambers, Cynthia A ^b   Hozumi, Nobumichi ^b   Kerbel, Robert S ^a,c,e  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Medical Research Council of   (Canada)

^e Institut national du cancer du Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6;

ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; FIBROBLAST; GENETIC TRANSFECTION; GROWTH REGULATION; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IN VIVO STUDY; MELANOMA; MESENCHYME CELL; PRIORITY JOURNAL;

ANIMALS; DOWN-REGULATION; GROWTH SUBSTANCES; HUMANS; INTERLEUKIN-6; MELANOMA; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDES, ANTISENSE; TUMOR CELLS, CULTURED;

EID: 0029737047     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Tabibzadeh, S. S., Poubouridis, D., May, L. T., and Sehgal, P. B. Interleukin-6 immunoreactivity in human tumors. Am. J. Pathol., 135: 427-433, 1989.
2. Takenawa, J., Kaneko, Y., Fukumoto, M., Hirano, T., Fukuyama, H., Nakayama, H., Fujita, J., and Yoshida, O. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J. Natl. Cancer Inst., 83: 1668-1672, 1991.
3. Van Meir, E., Sawarmura, Y., Diserens, A-C., Hamou, M-F., and de Tribolet, N. Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res., 50: 6683-6688, 1990.
4. Shirota, K., LeDuy, L., Yuan, S., and Jothy, S. Interleukin-6 and its receptor are expressed in human intestinal epithelial cells. Virchows Arch. B Cell Pathol., 58: 303-308, 1990.
5. Burger, R. A., Grosen, E. Z., Ioli, G. R., Van Eden, M. E., Park, M., Berman, M. L., Manetta, A., Disaia, P. J., Granger, G A., and Gatanaga, T. Spontaneous release of interleukin-6 by primary cultures of lymphoid and tumor cell populations purified from human ovarian carcinoma. J. Interferon Cytokine Res., 15: 255-260, 1995.
6. Schmitter, D , Lauber, B., Fagg, B., and Stahel, R. A. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int. J. Cancer, 51: 296-301, 1992.
7. Miki, S., Iswano, M., Miki, Y., Yamamoto, M., Tang, B., Yokokawa, K., Sonoda, T., Hirano, T., and Kishimoto, T. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett., 250: 607-610, 1989.
8. van Schweinitz, D., Hadam, M. R., Welte, K., Mildenberger, H., and Pietsch, T. Production of interleukin-1β and interleukin-6 in hepatoblastoma. Int. J. Cancer, 53: 728-734, 1993.
9. Siegal, C. B., Schwab, G., Nordan, R P., FitzGerald, D. J., and Pastan, I. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res., 50: 7786-7788, 1990.
10. Watson, J. M., Sensintaffar, J. L., Berek, J. S., and Martinez-Maza, O. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res., 50. 6959-6965, 1990.
11. Baffet, G., Braciak, T A., Fletcher, R. G., Gauldie, J., Fey, G. H., and Northemann, W. Autocrine activity of interleukin 6 secreted by hepatocarcinoma cell lines. Mol. Biol. & Med., 8: 141-156, 1991.
12. Eustace, D., Han, X., Gooding, R., Rowbottom, A., Riches, P., and Heyderman, E. Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol. Oncol., 50: 15-19, 1993.
13. Cornil, L, Theodorescu, D., Man, S., Herlyn, M., Jambrosic, J., and Kerbel, R. S. Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc. Natl. Acad. Sci. USA, 88: 6028-6032, 1991.
14. Rak, J. W., Hegmann, E. J., Lu, C., and Kerbel, R. S. Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during disease progression. J. Cell. Physiol., 159: 245-255, 1994.
15. Mullen, C. A., Coale, M. M., Levy, A. T., Stetler-Stevenson, W. G., Liotta, L. A., Brandt, S., and Blaese, R. M Fibrosarcoma cells transduced with the IL-6 gene exhibit reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. Cancer Res., 52: 6020-6024, 1992.
16. Katz, A., Shulman, L. M., Revel, M., Feldman, M., and Eisenbach, L. Combined therapy with IL-6 and inactivated tumor cells suppresses metastasis in mice bearing 3LL lung carcinomas. Int. J. Cancer, 53: 812-818, 1993.
17. Armstrong, C. A., Murray, N., Kennedy, M., Koppula, S. V., Tara, D., and Ansel, J. C. Melanoma-derived interleukin 6 inhibits in vivo melanoma growth. J. Invest. Dermatol., 102: 278-284, 1994
18. Tamura, S., Ouchi, K. F., Mon, K., Endo, M., Matsumoto. T., Eda, H., Tanaka, Y., Ishitsuka, H., Tokita, H., and Yamaguchi, K. Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft. Clin. Cancer Res., 1: 1353-1358, 1995.
19. Borsellino, N., Belldegrum, A., and Bonavida, B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res., 55: 4633-4639, 1995.
20. Veldhuis, G. J., Willemse, P. H. B., Sleifer, D. T., van der Graaf, W. T. A., Groen, H. J. M., Limburg, P. C., Mulder, N. H., and de Vries, E. G. E. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer of non-small-cell lung cancer. J. Clin. Oncol., 13: 2585-2593, 1995.
21. Herlyn, M. Human melanoma: development and progression. Cancer Metastasis Rev., 9: 101-112, 1990.
22. Herlyn, M., Kath, R., Williams, N., Valyi-Nagy, I., and Rodeck, U. Growth regulatory factors for normal, premalignant, and malignant human cells in vitro. Adv. Cancer Res., 54: 213-234, 1989.
23. Herlyn, M. Tumor progression in the melanocytic system. In: Molecular and Cellular Biology of Melanoma, pp. 21-43. Austin, TX: R. G. Landes Co., 1993.
24. Halaban, R., Kwon, B., Ghosh, S., Delli Bovis, P., and Baird, A. bFGF as an autocrine growth factor for human melanocytes. Oncogene Res.. 3: 177-186, 1988.
25. Becker, D., Meier, C. B., and Herlyn, M. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J., 8: 3685-3691, 1989.
26. Richmond, A., Balentien, E., Thomas, H. G., Glags, G., Barton, D. E., Spiess, J., Bordoni, R., Francke, U., and Derynck, R. Molecular characterization and chromosomal mapping of melanoma growth-stimulatory activity, a growth factor structurally related to β-thromboglobulin. EMBO J., 7: 2025-2033, 1988.
27. Schadendorf, D., Moller, A., Algermissen, B., Worm, M., Sticherling, M., and Czarnetzki, B. M. Interleukin 8 (IL-8) produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J. Immunol., 151: 2667-2675, 1993.
28. Kerbel, R. S. Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer: malignant melanoma as a paradigm. Am. J. Pathol., 141: 519-524, 1992.
29. Lu, C., Vickers, M. F., and Kerbel, R. S. Interleukin-6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc. Natl. Acad. Sci. USA, 89: 9215-9219, 1992.
30. Lu, C., Rak, J. W., Kobayashi, H., and Kerbel, R. S. Increased resistance to oncostatin M-induced growth inhibition of human melanoma cell lines derived from advanced-stage lesions. Cancer Res., 53: 2708-2711, 1993.
31. MacDougall, J., and Kerbel, R. S. Responsiveness of normal/dysplastic melanocytes and melanoma cells from different lesional stages of disease progression to the growth inhibitory effects of TGF-β. Mol. Cell. Differ., 1. 21-40, 1993.
32. Kobayashi, H., Man, S., MacDougall, J. R., Graham, C. H., Lu, C., and Kerbel, R. S. Variant sublines of early-stage human melanomas selected for tumorigenicity in nude mice express a multicytokine resistant phenotype. Am. J. Pathol., 144: 776-786, 1994.
33. Lu, C., and Kerbel, R. S. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J. Cell Biol., 120: 1281-1288, 1993.
34. Colombo, M. P., Maccalli, C., Mattei, S., Melani, C., Radrizzani, M., and Parmiani, G. Expression of cytokine genes, including IL-6, in human malignant melanoma cell lines. Melanoma Res., 2: 181-189, 1992.
35. Stein, C., and Kreig, A. Problems in the interpretation of data derived from the in vitro use of antisense oligonucleotides. Antisense Res., 4: 67-69, 1994.
36. Gura, T. Antisense has growing pains. Science (Washington DC), 270: 575-578, 1995.
37. Stein, C. A. Does antisense exist? Nat. Med., 1: 1119-1121, 1995.
38. Wagner, R. W. The state of the art in antisense research Nat. Med., 1: 1116-1118, 1995.
39. Chambers, C. A., Kang, J., and Hozumi, N. Ectopic lymphokine gene expression in human peripheral blood lymphocytes in vivo. Proc. Natl. Acad. Sci. USA, 89: 1026-1030, 1992.
40. Hirano, T., Yasukawa, K., Harada, H., Taga, T., Watanabe, Y., Matsuda, T., Kashiwamura, S., Nakajima, K., Koyama, K., Iwamatsu, A., Tsunasawa, S., Sakiyama, F., Matsui, H., Takahara, Y., Taniguchi, T., and Kishimoto, T. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature (Lond.), 324: 73-76, 1986.
41. Kang, J., Wither, J., and Hozumi, N. Long-term expression of a T-cell receptor β-chain gene in mice reconstituted with retrovirus-infected hematopoietic stem cells. Proc. Natl. Acad. Sci. USA, 87: 9803-9807, 1990.
42. Tso, Y. Y., Sun, X. H., Kao, T. H., Reece, K. S., and Wu, R. Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene. Nucleic Acids Res., 13: 2485-2502, 1985.
43. Cornil, I., Man, S., Fernandez, B., and Kerbel, R. S. Enhanced tumorigenicity, melanogenesis, and metastases of a human malignant melanoma after subdermal implantation in nude mice. J. Natl. Cancer Inst., 81: 938-944, 1989.
44. Rak, J. W., McEachern, D., and Miller, F R. Sequential alteration of peanut agglutinin binding-glycoprotein expression during progression of murine mammary neoplasia. Br. J. Cancer, 65: 641-648, 1992.
45. Wu, S , Boyer, C. M., Whitaker, R. S., Berchuck, A., Wiener, J. R., Weinberg, J. B., and Blast, R. C. Tumor necrosis factor α as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor α expression. Cancer Res., 53: 1939-1944, 1993.
46. Spriggs, D., Imamura, K., Rodriguez, C., Horiguchi, J., and Kufe, D. W. Induction of tumor necrosis factor expression and resistance in human breast tumor cell line. Proc. Natl. Acad. Sci. USA, 84: 6563-6566, 1987.
47. Kath, R., Rodeck, U., Parmiter, A., and Herlyn, M. Growth factor independence in vitro of primary melanoma cells from advanced but not early or intermediate lesions. Cancer Ther. Control. 1: 179-191, 1991.
48. Kerbel, R. S., Man, M. S., and Dexter, D. A model of human cancer metastasis: extensive spontaneous and artificial metastasis of human pigmented and derived variant sublines in nude mice. J. Natl. Cancer Inst.. 72: 93-108, 1984.
49. Alroy, J., Goyal, V., and Skutelsky, E. Lectin histochemistry pf mammalian endothelium. Histochemistry, 86: 603-607, 1987.
50. Motro, B., Itin, A., Sachs, L., and Keshet, E. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc. Natl. Acad. Sci. USA, 87: 3092-3096, 1990.
51. Aquilar-Santelises, M., Magnusson, R , Sevenson, S- B., Loftenius, A., Andersson, B., Mellstedt, H., and Jondal, M. Expression of interleukin-1α, interleukin-1β and interleukin-6 in chronic B lymphocytic leukaemia (B-CLL) cells from patients at different stages of disease progression. Clin. Exp. Immunol., 84: 422-428, 1991
52. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaku, H., Tang, B., Tanabe, O., Tanada, H., Kuramoto, A., and Kishimoto, T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature (Lend.), 332: 83-85, 1988.
53. Levy, Y., Tsapis, A., and Brouet, J-C. Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines. J. Clin. Invest , 88: 696-699, 1991.
54. Yee, C., Biondi, A., Wang. X. H., Iscove, N. N., Sousa, J., Aarden, L. A., Wong, G. G., Clark, S. C., Messner, H. A., and Minden, M. D. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood, 74: 798-804, 1989.
55. Liu, Y., Michalopoulos, G. K., and Zarnegar, R. Structural and functional characterization of the mouse hepatocyte growth factor gene promoter. J. Biol. Chem., 209: 4152-4160, 1994.
56. Halaban, R., Rubin, J. S., Funasaka, Y., Cobb, M., Boulton, T., Faletto, D., Rosen, E., Chan, A., Yoko, K, White, W., Cook, C., and Moellmann, G. Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells. Oncogene, 7: 2195-2206, 1992.
57. Lichtenstein, A., Tu, Y., Fady, C., Vescio, R., and Berenson, J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell. Immunol., 162: 248-255, 1995.
58. Liu, J., Li, H., de Tribolet, N., Jaufeerally, R., Hamou, M. F., and Van Meir, E. G. IL-6 stimulates growth and inhibits constitutive, protein synthesis-independent apoptosis of murine B-cell hybridoma 7TD1. Cell. Immunol., 155: 428-435, 1994.
59. Yonish-Rouach, E , Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (Lond.), 352: 345-347, 1991
60. L. Cancer Res., 55: 2262-2265, 1995
61. Hewitt, H. B. Animal tumor models and their relevance to human tumor immunology. J. Biol. Response Modif., 1: 107-119, 1982.
62. Hewitt, H. B. The choice of animal tumors for experimental studies of cancer therapy. Adv. Cancer Res., 27: 149-200, 1978.